Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines

Yi Guo; Hriday Bera; Changzhi Shi; Li Zhang; Dongmei Cun; Mingshi Yang

doi:10.1016/j.apsb.2021.05.015

Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines

Yi Guo, Hriday Bera, Changzhi Shi, Li Zhang, Dongmei Cun^*, Mingshi Yang

^*Corresponding author for this work

Pharmaceuticals, processes and products

Research output: Contribution to journal › Review › Research › peer-review

82 Citations (Scopus)

19 Downloads (Pure)

Abstract

Pulmonary administration route has been extensively exploited for the treatment of local lung diseases such as asthma, chronic obstructive pulmonary diseases and respiratory infections, and systemic diseases such as diabetes. Most inhaled medicines could be cleared rapidly from the lungs and their therapeutic effects are transit. The inhaled medicines with extended pulmonary exposure may not only improve the patient compliance by reducing the frequency of drug administration, but also enhance the clinical benefits to the patients with improved therapeutic outcomes. This article systematically reviews the physical and chemical strategies to extend the pulmonary exposure of the inhaled medicines. It starts with an introduction of various physiological and pathophysiological barriers for designing inhaled medicines with extended lung exposure, which is followed by recent advances in various strategies to overcome these barriers. Finally, the applications of the inhaled medicines with extended lung exposure for the treatment of various diseases and the safety concerns associated to various strategies to extend the pulmonary exposure of the inhaled medicines are summarized.

Original language	English
Journal	Acta Pharmaceutica Sinica B
Volume	11
Issue number	8
Pages (from-to)	2565-2584
ISSN	2211-3835
DOIs	https://doi.org/10.1016/j.apsb.2021.05.015
Publication status	Published - 2021

Bibliographical note

Funding Information:
We thankfully acknowledge the Liaoning Pan Deng Xue Zhe scholarship for the financial support (China). Dongmei Cun thanks the financial support from the Guiding Project for Science and Technology of Liaoning Province (No. 2019-ZD-0448 , China), and Minister of Education Chunhui Program (China). Hriday Bera thanks the National Natural Science Foundation of China (Nos. 81850410554 and 82050410448).

Publisher Copyright:
© 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences

Keywords

Inhaled sustained release formulations
Local lung diseases
Pharmaceutical strategies
Pulmonary clearance pathways
Pulmonary drug delivery
Pulmonary exposure
Pulmonary safety
Systemic diseases

Access to Document

10.1016/j.apsb.2021.05.015Licence: CC BY

FulltextFinal published version, 1.87 MBLicence: CC BY-NC-ND

Cite this

@article{21ade89904224d498bdb0a3fc586f30e,

title = "Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines",

abstract = "Pulmonary administration route has been extensively exploited for the treatment of local lung diseases such as asthma, chronic obstructive pulmonary diseases and respiratory infections, and systemic diseases such as diabetes. Most inhaled medicines could be cleared rapidly from the lungs and their therapeutic effects are transit. The inhaled medicines with extended pulmonary exposure may not only improve the patient compliance by reducing the frequency of drug administration, but also enhance the clinical benefits to the patients with improved therapeutic outcomes. This article systematically reviews the physical and chemical strategies to extend the pulmonary exposure of the inhaled medicines. It starts with an introduction of various physiological and pathophysiological barriers for designing inhaled medicines with extended lung exposure, which is followed by recent advances in various strategies to overcome these barriers. Finally, the applications of the inhaled medicines with extended lung exposure for the treatment of various diseases and the safety concerns associated to various strategies to extend the pulmonary exposure of the inhaled medicines are summarized.",

keywords = "Inhaled sustained release formulations, Local lung diseases, Pharmaceutical strategies, Pulmonary clearance pathways, Pulmonary drug delivery, Pulmonary exposure, Pulmonary safety, Systemic diseases",

author = "Yi Guo and Hriday Bera and Changzhi Shi and Li Zhang and Dongmei Cun and Mingshi Yang",

note = "Funding Information: We thankfully acknowledge the Liaoning Pan Deng Xue Zhe scholarship for the financial support (China). Dongmei Cun thanks the financial support from the Guiding Project for Science and Technology of Liaoning Province (No. 2019-ZD-0448 , China), and Minister of Education Chunhui Program (China). Hriday Bera thanks the National Natural Science Foundation of China (Nos. 81850410554 and 82050410448). Publisher Copyright: {\textcopyright} 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences",

year = "2021",

doi = "10.1016/j.apsb.2021.05.015",

language = "English",

volume = "11",

pages = "2565--2584",

journal = "Acta Pharmaceutica Sinica B (Online)",

issn = "2211-3843",

publisher = "Elsevier",

number = "8",

}

TY - JOUR

T1 - Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines

AU - Guo, Yi

AU - Bera, Hriday

AU - Shi, Changzhi

AU - Zhang, Li

AU - Cun, Dongmei

AU - Yang, Mingshi

N1 - Funding Information: We thankfully acknowledge the Liaoning Pan Deng Xue Zhe scholarship for the financial support (China). Dongmei Cun thanks the financial support from the Guiding Project for Science and Technology of Liaoning Province (No. 2019-ZD-0448 , China), and Minister of Education Chunhui Program (China). Hriday Bera thanks the National Natural Science Foundation of China (Nos. 81850410554 and 82050410448). Publisher Copyright: © 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences

PY - 2021

Y1 - 2021

N2 - Pulmonary administration route has been extensively exploited for the treatment of local lung diseases such as asthma, chronic obstructive pulmonary diseases and respiratory infections, and systemic diseases such as diabetes. Most inhaled medicines could be cleared rapidly from the lungs and their therapeutic effects are transit. The inhaled medicines with extended pulmonary exposure may not only improve the patient compliance by reducing the frequency of drug administration, but also enhance the clinical benefits to the patients with improved therapeutic outcomes. This article systematically reviews the physical and chemical strategies to extend the pulmonary exposure of the inhaled medicines. It starts with an introduction of various physiological and pathophysiological barriers for designing inhaled medicines with extended lung exposure, which is followed by recent advances in various strategies to overcome these barriers. Finally, the applications of the inhaled medicines with extended lung exposure for the treatment of various diseases and the safety concerns associated to various strategies to extend the pulmonary exposure of the inhaled medicines are summarized.

AB - Pulmonary administration route has been extensively exploited for the treatment of local lung diseases such as asthma, chronic obstructive pulmonary diseases and respiratory infections, and systemic diseases such as diabetes. Most inhaled medicines could be cleared rapidly from the lungs and their therapeutic effects are transit. The inhaled medicines with extended pulmonary exposure may not only improve the patient compliance by reducing the frequency of drug administration, but also enhance the clinical benefits to the patients with improved therapeutic outcomes. This article systematically reviews the physical and chemical strategies to extend the pulmonary exposure of the inhaled medicines. It starts with an introduction of various physiological and pathophysiological barriers for designing inhaled medicines with extended lung exposure, which is followed by recent advances in various strategies to overcome these barriers. Finally, the applications of the inhaled medicines with extended lung exposure for the treatment of various diseases and the safety concerns associated to various strategies to extend the pulmonary exposure of the inhaled medicines are summarized.

KW - Inhaled sustained release formulations

KW - Local lung diseases

KW - Pharmaceutical strategies

KW - Pulmonary clearance pathways

KW - Pulmonary drug delivery

KW - Pulmonary exposure

KW - Pulmonary safety

KW - Systemic diseases

U2 - 10.1016/j.apsb.2021.05.015

DO - 10.1016/j.apsb.2021.05.015

M3 - Review

C2 - 34522598

AN - SCOPUS:85111482770

VL - 11

SP - 2565

EP - 2584

JO - Acta Pharmaceutica Sinica B (Online)

JF - Acta Pharmaceutica Sinica B (Online)

SN - 2211-3843

IS - 8

ER -